Reporting on discovery of an internal immune brake molecule and the preclinical antibody strategies developed to counter it in cancer.
Key Takeaways
- SLAMF6 was identified as a T cell inhibitory receptor accelerating immune exhaustion in cancer
- Monoclonal antibodies were developed to block SLAMF6 and revive antitumor T cell activity in mice
- Antibodies outperformed prior SLAMF6-targeting approaches and will enter early-stage clinical testing